Covid threatens those whose immune systems can’t make enough neutralizing antibodies to fight off the viral invaders. But what if scientists could make super-potent antibodies in the lab and infuse them into newly infected patients? That’s exactly what the first FDA-authorized coronavirus antibody treatment has achieved. Its maker, Eli Lilly, has generated clinical evidence that their therapy can significantly reduce COVID hospitalization rates when taken early.
Podden och tillhörande omslagsbild på den här sidan tillhör Biotechnology Innovation Organization. Innehållet i podden är skapat av Biotechnology Innovation Organization och inte av, eller tillsammans med, Poddtoppen.
